文献速递骨显像与常规 SPECT肿瘤 PET/CT放射性药物与辐射防护

多发性骨髓瘤分期与疗效评估中18F-FDG PET/CT与全身MRI及骨骼检查的一致性比较

Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma.
PubMed 文献 · Clin Nucl Med · 2021-01-01

结果显示除颅骨外全身MRI和PET/CT在各部位发现的病灶均多于骨骼检查,两者在多数部位一致性良好或极好。

要点

  • 除颅骨外,全身MRI和18F-FDG PET/CT发现的病灶均多于骨骼检查
  • 全身MRI与PET/CT在多数部位和浆细胞瘤评估中一致性良好或极好
  • 全身MRI在骨髓压迫和血管坏死等并发症评估中优于PET/CT

核心结论

  • 多发性骨髓瘤患者检查应包含全身MRI和/或18F-FDG PET/CT,骨骼检查仅对颅骨有用。
  • 全身MRI与18F-FDG PET/CT是互补技术,因两者在几乎所有部位一致性良好。
  • 仍需根据患者特征个体化选择每种技术的适应证。

研究设计与样本

  • 患者接受骨骼检查、全身MRI和/或18F-FDG PET/CT检查,按解剖部位分析骨病灶并评估一致性。

主要发现

  • 除颅骨外,全身MRI和18F-FDG PET/CT在每个部位发现的病灶均多于骨骼检查。
  • 全身MRI与18F-FDG PET/CT在多数部位及浆细胞瘤研究中一致性良好或极好。
  • 全身MRI在并发症(骨髓压迫和血管坏死)评估中优于18F-FDG PET/CT。

临床怎么用

  • 多发性骨髓瘤初始分期和疗效评估应纳入全身MRI和/或18F-FDG PET/CT,而非仅依赖骨骼检查。
  • 颅骨病灶评估时骨骼检查仍有价值。
  • 根据患者特征个体化选择全身MRI或18F-FDG PET/CT,两者互补。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the agreement between whole-body (WB) magnetic resonance (MR) imaging, 18F-FDG PET/CT, and skeletal survey (SS) in patients with multiple myeloma (MM) for diagnosis, initial staging, response evaluation, and early detection of complications. METHODS: This is a retrospective cohort study including MM patients who were diagnosed, treated, and followed in 2 institutions. These patients were studied with SS, WB-MR, and/or 18F-FDG PET/CT. We studied bone lesions by anatomical locations and analyzed the concordance between SS and a tomographic technique (WB-MR or 18F-FDG PET/CT) and between both tomographic techniques (WB-MR and PET/CT). RESULTS: Forty-four MM patients with a mean age of 62.6 years (range, 38-85 years) were included from January 2012 to February 2016. Whole-body MR and 18F-FDG PET/CT found more lesions than SS in every location except in the skull. Concordance between WB-MR and 18F-FDG PET/CT was either good or excellent in most of the locations and in plasmacytoma studies. However, WB-MR was better than 18F-FDG PET/CT in the study of complications (medullar compression and vascular necrosis). CONCLUSIONS: Our results suggest the study of MM patients should include WB-MR and/or 18F-FDG PET/CT, whereas SS is only useful for the skull. Whole-body MR and 18F-FDG PET/CT are complementary techniques, because both of them show good concordance in almost every location. It is still necessary to individualize the indication of each technique according to patient characteristics.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gómez León N, Aguado Bueno B, Herreros Pérez M, et al. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma. Clin Nucl Med. 2021. PMID: 33534256. doi:10.1097/RLU.0000000000003512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。